Wells Fargo
VERV

Wells Fargo’s Verve Therapeutics VERV Stock Holding History

Wells Fargo’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-47,566
Closed -$534K – 7416
2025
Q2 		$534K Buy
47,566
+1,202
+3% +$6.85K ﹤0.01% 4092
2025
Q1 		$212K Buy
46,364
+942
+2% +$6.31K ﹤0.01% 4664
2024
Q4 		$256K Buy
45,422
+9,083
+25% +$51.2K ﹤0.01% 4645
2024
Q3 		$176K Buy
36,339
+1,400
+4% +$8.13K ﹤0.01% 4670
2024
Q2 		$171K Buy
34,939
+7,956
+29% +$50K ﹤0.01% 4622
2024
Q1 		$358K Buy
26,983
+10,381
+63% +$138K ﹤0.01% 4104
2023
Q4 		$231K Sell
16,602
-47,183
-74% -$585K ﹤0.01% 4378
2023
Q3 		$846K Buy
63,785
+3,314
+5% +$53.4K ﹤0.01% 3436
2023
Q2 		$1.13M Buy
60,471
+7,856
+15% +$131K ﹤0.01% 3381
2023
Q1 		$759K Buy
52,615
+50,055
+1,955% +$980K ﹤0.01% 3576
2022
Q4 		$49.5K Sell
2,560
-4,027
-61% -$107K ﹤0.01% 4861
2022
Q3 		$227K Buy
6,587
+6,006
+1,034% +$192K ﹤0.01% 4172
2022
Q2 		$9K Sell
581
-3,566
-86% -$55.2K ﹤0.01% 5808
2022
Q1 		$94K Sell
4,147
-456
-10% -$13K ﹤0.01% 5366
2021
Q4 		$170K Buy
4,603
+4,524
+5,727% +$190K ﹤0.01% 5357
2021
Q3 		$4K Sell
79
-21
-21% -$1.24K ﹤0.01% 6459
2021
Q2 		$6K Buy
+100
New +$4.15K ﹤0.01% 6299

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo's VERV Position: Q3 2025 in Review

Wells Fargo sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 47,566 shares — an estimated $534K sold.

Wells Fargo first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $1.13M in Q2 2023. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Wells Fargo reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wells Fargo sold 47,566 Verve Therapeutics shares in Q3 2025, an estimated $534K.
  • Wells Fargo first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Wells Fargo's Verve Therapeutics position peaked at $1.13M in Q2 2023.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.